Skip to content
MS
Sign in
unreviewed

LDL receptor (LDLR)

0 reactions · 0 pathways

What it does, reaction by reaction

0 reactions

This enzyme appears only in the regulation table, with no catalysed step recorded.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

1 entries

Lipoprotein Metabolism (Exogenous and Endogenous Pathways: chylomicrons, VLDL, LDL, HDL)

Accelerated by

SREBP-2 when hepatocyte cholesterol is low; receptor recycling

Inhibited by

Intracellular cholesterol; PCSK9-mediated degradation

Hormonal control

Insulin can increase expression; statin-mediated cholesterol depletion strongly increases LDLR through SREBP-2

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Antibodies to watch in 2026.

    Crescioli S, Kaplon H, Chenoweth A, Hsu YS, Pinto K, Kapoor V, Reichert JM. · 2026-01-21

    cited 24× open access unreviewed
  2. 2
    Vascular calcification: pathogenic mechanisms, signaling crosstalk and translational therapeutics.

    Hua R, Qiao B, Liu X, Jiang B, Wu J, Zhang C, Liu H, Wang B, Wei S, Chen Y. · 2026-10-02

    open access unreviewed
  3. 3
    COPI Coatomer Regulates Several Steps of HDL Metabolism.

    Panteloglou G, Zanoni P, Law CS, Woods B, Othman A, Yalcinkaya M, Norrelykke SF, Rzepiela AJ, Stoma S, Steble… · 2026-08-13

    unreviewed
  4. 4
    S100A11 regulates hepatic cholesterol metabolism and promotes steatohepatitis via noncanonical SREBP2 signaling.

    Zhan M, Xu X, Wu H, Fan Q, Lu H, Li C, Zhang L, Zhu T, Shen Y, Liu J, He Y, Wu Y, Zhang J, Zou X, Liang B. · 2026-08-04

    open access unreviewed
  5. 5
    Post‑translational modifications in atherosclerosis: Roles, mechanisms and therapeutic potential (Review).

    Xu X, Ma F, Yu W. · 2026-07-31

    open access unreviewed
  6. 6
    Aptamer targeting proprotein convertase subtilisin/kexin type 9: in vivo efficacy in a hypercholesterolemic rat model

    Milasi Y, Sakhaei F, Palizban A. · 2026-09-08

    open access unreviewed
  7. 7
    Levonorgestrel-ethinyl estradiol impairs hepatic lipid clearance to induce hypercholesterolemia via PCSK9-mediated LDLR and CD36 dysregulation.

    Li B, Ye C, Wang Z, Zhang J, Fan Z, Huo Y, Wang X, Lv F. · 2026-09-30

    unreviewed
  8. 8
    Putative protective role of <i>PCSK9</i> variants in a multigenerational family with familial hypercholesterolemia.

    Rodríguez-Nóvoa S, Martínez Hernández P, Hidalgo Mayoral I, Herranz Cecilia A, Rodríguez Roca N, Carazo Álvar… · 2026-09-05

    open access unreviewed
  9. 9
    Modulation of Hepatic Cholesterol-Related Pathways by <i>Ophiocordyceps sinensis</i> and Coenzyme Q10 in a Sequential Gut-Liver In Vitro Model.

    Mulè S, Galla R, Musu M, Parini F, Molinari C, Uberti F. · 2026-09-15

    open access unreviewed
  10. 10
    Apolipoprotein E Mimetic Peptide-Mediated Modulation of Lipid Homeostasis.

    Patel DR, Martin CL, Anantharamaiah GM, Aller SG. · 2026-09-17

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.